News

Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
(President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as "Ajinomoto") has been conducting joint ...
Ajinomoto Bio-Pharma Services: Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
AJICAP® Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody DrugsTOKYO, May 7, 2025 ...